These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 18451237)

  • 21. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
    J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
    [No Abstract]   [Full Text] [Related]  

  • 24. [Gastrointestinal stromal tumor].
    Nishida T; Ohmori T; Matsuda H
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):331-6. PubMed ID: 15045935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
    Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [GIST refractory to imatinib treatment].
    Onozawa Y; Terashima M
    Gan To Kagaku Ryoho; 2011 May; 38(5):738-43. PubMed ID: 21566433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M; Demertzis N; Iakovidou I; Kottakis S
    Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of imatinib in patients with small cell lung cancer.
    Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of imatinib in unresectable hepatocellular carcinoma.
    Lin AY; Fisher GA; So S; Tang C; Levitt L
    Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
    Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
    Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
    Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.